See more : HF Sinclair Corporation (HFC) Income Statement Analysis – Financial Results
Complete financial analysis of Regen BioPharma, Inc. (RGBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Regen BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Royal Gold, Inc. (0KXS.L) Income Statement Analysis – Financial Results
- Aceso Life Science Group Limited (0474.HK) Income Statement Analysis – Financial Results
- HSINO TOWER GROUP CO LTD (601096.SS) Income Statement Analysis – Financial Results
- Tech-Bank Food Co., Ltd. (002124.SZ) Income Statement Analysis – Financial Results
- Singapore Airlines Limited (C6L.SI) Income Statement Analysis – Financial Results
Regen BioPharma, Inc. (RGBP)
About Regen BioPharma, Inc.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236.56K | 236.56K | 235.52K | 171.19K | 110.00K | 110.00K | 100.00K | 110.00K | 100.00K | 192.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 77.22K | 0.00 | 50.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 159.35K | 236.56K | 185.52K | 146.19K | 110.00K | 110.00K | 100.00K | 110.00K | 100.00K | 192.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 67.36% | 100.00% | 78.77% | 85.40% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 153.69K | 212.30K | 275.39K | 36.70K | 13.29K | 45.61K | 374.44K | 1.15M | 671.10K | 282.30K | 23.87K | 8.39K | 42.52K |
| General & Administrative | 423.85K | 651.21K | 299.73K | 335.26K | 306.03K | 821.18K | 1.15M | 1.47M | 2.39M | 1.89M | 682.49K | 311.44K | 358.74K |
| Selling & Marketing | 0.00 | 60.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 423.85K | 711.21K | 299.73K | 335.26K | 306.03K | 821.18K | 1.15M | 1.47M | 2.39M | 1.89M | 682.49K | 311.44K | 358.74K |
| Other Expenses | 0.00 | 1.00 | 62.70K | 1.00 | 0.00 | 1.73K | -270.20K | 53.87K | -4.75M | 1.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 577.53K | 923.51K | 575.12K | 371.96K | 319.32K | 866.79K | 1.53M | 2.62M | 3.06M | 2.17M | 706.35K | 319.84K | 401.26K |
| Cost & Expenses | 654.75K | 923.51K | 575.12K | 371.96K | 319.32K | 866.79K | 1.53M | 2.62M | 3.06M | 2.17M | 706.35K | 319.84K | 401.26K |
| Interest Income | 0.00 | 0.00 | 455.00 | 230.00 | 942.93K | 1.30K | 10.23K | 1.86K | 1.20K | 1.15K | 233.00 | 0.00 | 0.00 |
| Interest Expense | -72.45K | 309.45K | 209.79K | 367.03K | 942.93K | 1.70M | 1.56M | 591.06K | 46.42K | 21.69K | 2.21K | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 1.90M | 339.61K | 200.77K | 209.32K | 874.91K | 1.43M | 2.53M | 2.96M | 1.15K | 233.00 | 319.84K | 401.26K |
| EBITDA | -418.19K | 1.22M | 2.99M | -6.40M | 4.36M | -753.75K | -3.15M | -2.46M | 0.00 | -2.19M | -706.12K | -35.20K | 234.07K |
| EBITDA Ratio | -176.78% | 514.02% | -136.70% | -117.14% | -190.29% | -685.23% | -1,685.75% | -2,231.96% | -7,704.17% | -1,030.28% | 0.00% | 0.00% | 0.00% |
| Operating Income | -418.19K | -686.95K | -339.61K | -200.77K | -209.32K | -756.79K | -1.43M | -2.51M | -2.96M | -1.98M | -706.35K | -319.84K | -401.26K |
| Operating Income Ratio | -176.78% | -290.39% | -144.20% | -117.28% | -190.29% | -687.99% | -1,425.78% | -2,282.62% | -2,956.96% | -1,030.87% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -449.06K | 1.84M | 2.78M | -6.56M | 3.62M | -1.87M | -3.29M | -3.33M | -456.56K | -231.44K | -50.00K | -35.20K | 0.00 |
| Income Before Tax | -867.25K | 1.16M | 2.44M | -6.77M | 3.41M | -2.62M | -4.72M | -5.84M | -7.75M | -11.20M | -756.35K | -355.03K | -401.26K |
| Income Before Tax Ratio | -366.61% | 488.89% | 1,037.52% | -3,951.79% | 3,104.02% | -2,384.71% | -4,715.20% | -5,308.22% | -7,750.59% | -5,830.81% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | -3.05M | 366.80K | 1.63M | 1.70M | 3.02M | 589.21K | 45.22K | 20.54K | 1.98K | -319.84K | 0.00 |
| Net Income | -867.25K | 1.02M | 5.49M | -7.13M | 1.79M | -4.32M | -4.72M | -5.84M | -7.75M | -11.20M | -756.35K | -355.03K | -401.26K |
| Net Income Ratio | -366.61% | 432.66% | 2,330.99% | -4,166.05% | 1,626.00% | -3,931.03% | -4,715.20% | -5,308.22% | -7,750.59% | -5,830.81% | 0.00% | 0.00% | 0.00% |
| EPS | -0.21 | 0.29 | 1.75 | -3.55 | 1.90 | -3.13 | -46.50 | -61.93 | -90.94 | -190.43 | -21.93 | -28.10 | 0.00 |
| EPS Diluted | -0.21 | 0.29 | 1.75 | -3.55 | 1.90 | -3.13 | -46.50 | -61.93 | -90.94 | -190.43 | -21.93 | -28.10 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 3.54M | 3.14M | 2.01M | 939.90K | 1.38M | 101.39K | 94.28K | 85.23K | 58.79K | 34.49K | 12.63K | 0.00 |
| Weighted Avg Shares Out (Dil) | 0.00 | 3.54M | 3.14M | 2.01M | 939.90K | 1.38M | 101.39K | 94.28K | 85.23K | 58.79K | 34.49K | 12.63K | 0.00 |
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™
Targeting Transformative Solutions for Aplastic Anemia and Beyond SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate ™ , the company's...
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024
Regen BioPharma, Inc. invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , April 2, 2024 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC...
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , Jan. 8, 2024 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC...
Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html). This program is designed to create chimeric antigen T-cells that silence the gene...
Regen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO, Calif.
Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
Autoimmunity to be Targeted SAN DIEGO , Oct. 25, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html) while also identifying new,...
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
BALTIMORE, MD / ACCESSWIRE / October 4, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Regen BioPharma, Inc....
Studies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies
Initial Design and Testing Complete SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) had previously discussed initiation of a series of experiments to validate its DuraCAR CAR-T cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html).
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.
Source: https://incomestatements.info
Category: Stock Reports